NCT01983033

Brief Summary

Repetitive negative thinking (RNT) plays an important role in different psychiatric disorders, such as depressive and anxiety disorders, complicated grief, posttraumatic stress disorders, anorexia nervosa. RNT is seen as a vulnerability factor in the onset, duration, severity and relapse of those disorders. Although there is a lot of theoretical research, it is unknown if a group training protocol addressing RNT has an additional effect on Treatment as Usual (TAU) of patients with GAD or Depressive disorder. Our hypothesis is that a training intervention will show a significant effect on declined RNT activity (measured by PSWQ and LARRS), reduced identification with worrying/rumination (measured by CFQ-13 and a Visual Analogue Scale), and reduced scores on metacognitions questionnaire (MCV Dutch version of the MCQ), when compared to TAU (medication, psychotherapy or a combination of both treatments). Further we expect that this effect on RNT will not be temporary and the beneficial effects will remain present over a longer time (9 months). Our third hypothesis claims that reduced RNT will have an effect on Quality of Life, self-esteem and depressive and anxiety scores (measured respectively by WHO-QoL, Rosenberg Self Esteem Questionnaire, BDI-II and STAI; all of them in Dutch version). Fourth hypothesis concerns the effect of the training in the functioning on a neurobiological level. Here we expect that the beneficial effects of training on RNT will increase top-down prefrontal (dorsolateral) cortical control over an overactive bottom-up limbic system. To examine these neurobiological effects, we apply a multimodal approach where we combine resting state fMRI, structural MRI such as diffuse tensor imaging (DTI), anterior spin labelling (ASL). Further, in our department we developed an audio critique task where participants hear different kinds of critique amongst some of negative valence which will be especially problematic for ruminative patients reflecting difficulties and differences these top-down/bottom-up processes when compared to a healthy control group at baseline. Further, we hypothesize that only when coping with RNT is successful these neuronal processes will normalize. We do not expect changes in the waiting list group. To examine these clinical and neuronal effects, people suffering from GAD and/or depression will be allocated by randomisation to an active treatment condition (ATC) and a waiting list control group (WLC). All the participants will be patients treated by general practitioner, psychologist or psychiatrist. Training exists of 8 sessions in group (max 12 participants) on a weekly basis, except for the last session, which takes place after one month). During the training people will get information on RNT, they will be trained in re-allocation of their attention, will receive some basic ideas about becoming aware of dysfunctional thinking and learn coping strategies such as stimulus control and engaging in positive activity. Assessments will take place before and after treatment for the ATC. The WLC will be measured at the start of the WLC and 12 weeks later. Measurement takes place by means of questionnaires and fMRI. During the fMRI, people will undergo a resting state paradigm and some tasks triggering RNT. 3 and 9 months after the group treatment, participants will be evaluated again on RNT by means of questionnaires. Participants in WLC will receive group treatment from the moment the parallel active treatment condition is ended (e.g. after 12 weeks). This group will be evaluated immediately after training and at 3 and 9 months follow-up. At the end of the training, after the 8th session, two participants per run will be asked to cooperate in a qualitative in-depth interview. We are interested in linking results with the group training with some factors such as quantity of sessions, degree of active participation in between sessions. We are also interested in defining which interventions are perceived as most useful and if there is a link between disorder and the usefulness of some interventions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2013

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2013

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 6, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 13, 2013

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

May 25, 2017

Status Verified

May 1, 2017

Enrollment Period

3.2 years

First QC Date

November 6, 2013

Last Update Submit

May 23, 2017

Conditions

Outcome Measures

Primary Outcomes (5)

  • change in repetitive negative thinking

    degree of repetitive negative thinking (PSWQ Dutch version)

    at baseline, at the end of active treatment (12 weeks), at 3 months follow-up and at 9 months follow-up

  • change in repetitive negative thinking

    degree of repetitive negative thinking (LARRS)

    at baseline, at the end of active treatment (12 weeks), at 3 months follow-up and at 9 months follow-up

  • change in repetitive negative thinking

    changes in metacognitions on RNT (MCV Dutch version of MCQ)

    at baseline, at the end of active treatment (12 weeks), at 3 months follow-up and at 9 months follow-up

  • change in repetitive negative thinking

    degree of identification/disengagement (CFQ-13)

    at baseline, at the end of active treatment (12 weeks), at 3 months follow-up and at 9 months follow-up

  • change in repetitive negative thinking

    degree of identification/disengagement (VAS)

    at baseline, at the end of active treatment (12 weeks), at 3 months follow-up and at 9 months follow-up

Secondary Outcomes (5)

  • change in resting state fMRI

    at baseline and at the end of active treatment (12 weeks)

  • change in Quality of Life

    two weeks before active treatment,12 weeks after the start of the active treatment, 3 months after follow-up and 9 months after follow-up

  • change in self-esteem

    two weeks before active treatment,12 weeks after the start of the active treatment, 3 months after follow-up and 9 months after follow-up

  • change in depression and anxiety

    two weeks before active treatment/waiting list, 12 weeks after active treatment/waiting list, follow-up 3 and 9 months after active treatment

  • change in personality features

    two weeks before active treatment/waiting list, 12 weeks after the start of the active treatment/waiting list

Study Arms (2)

active treatment condition (ATC)

EXPERIMENTAL

training protocol 'drop it'

Behavioral: Drop It training session

waiting list control

OTHER

no treatment other than treatment as usual

Behavioral: treatment as usual

Interventions

8 training sessions in group, sessions of 90 minutes, 7 sessions weekly, plus 1 session after 1 month

active treatment condition (ATC)

12 weeks of no intervention other than treatment as usual

waiting list control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • GAD
  • depression or depression in remission

You may not qualify if:

  • other psychiatric pathology than GAD or depression screened by senior psychiatrist by means of MINI and psychiatric anamnesis
  • Abuse of alcohol, drugs or medication other than prescribed by GP or psychiatrist
  • no consent to participate in measurement (questionnaire or fMRI- for fMRI: except medical contra-indications)
  • Insufficient knowledge of the current language (Dutch)
  • Acute or chronic suicidality
  • Acute psychosis or manic depressive disorder
  • Not able to commit for the 8 sessions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ghent University Hospital

Ghent, 9000, Belgium

Location

MeSH Terms

Conditions

Generalized Anxiety DisorderDepressive DisorderDepressionAnxiety DisordersRumination Syndrome

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Mental DisordersMood DisordersBehavioral SymptomsBehaviorGastrointestinal DiseasesDigestive System DiseasesFeeding and Eating Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 6, 2013

First Posted

November 13, 2013

Study Start

October 1, 2013

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

May 25, 2017

Record last verified: 2017-05

Locations